EU's CHMP Recommends Approval of TEMODAL(R) (Temozolomide) for the Most Common and Aggressive Form of Brain Cancer

... Schering-Plough Corporation (NYSE: SGP) reported that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending approval of TEMODAL(R) (temozolomide) Capsules for first-line use in the treatment of patients with newly diagnosed glioblastoma multiforme (GBM), the most common form of brain cancer... click link for more info. ...